mirvetuximab soravtansine
Selected indexed studies
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. (N Engl J Med, 2023) [PMID:38055253]
- Mirvetuximab Soravtansine. (, 2006) [PMID:36512666]
- Mirvetuximab Soravtansine: First Approval. (Drugs, 2023) [PMID:36656533]
_Worker-drafted node — pending editorial review._
Connections
mirvetuximab soravtansine is a side effect of
Sources
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. (2023) pubmed
- Mirvetuximab Soravtansine. (2006) pubmed
- Mirvetuximab Soravtansine: First Approval. (2023) pubmed
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. (2021) pubmed
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. (2023) pubmed
- Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer. (2023) pubmed
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. (2023) pubmed
- Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations. (2024) pubmed
- Mirvetuximab Soravtansine-gynx. (2023) pubmed
- Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. (2023) pubmed